Delta 4

Delta 4 is a biotech startup based in Vienna, Austria, specializing in digital drug discovery and development. They combine systems biology, computational modeling, AI, and large-scale data to understand disease mechanisms and predict drug behavior in silico. Their primary focus is helping clients expand indications for existing drugs with known safety profiles to accelerate new treatment options.

The business operates out of Alser Straße 23/Top 30 in the Innere Stadt district of Vienna, Austria. They also maintain a Swiss presence at Roosstrasse 60 in Wollerau. Their core services include co-development of drug assets and research collaborations within consortia to identify biomarkers and drug targets.

Delta 4's proprietary artificial intelligence platform is called Hyper-C. This platform allows them to detect relationships between drugs with known safety profiles to identify new indications with unprecedented speed and accuracy. They also utilize a technology named Combo-C for screening and prioritizing drug combinations.

A typical project focused on a single use case, such as drug repositioning or biomarker discovery, takes about 4-6 months to complete. Longer collaborations or framework agreements can be established to cover multiple use cases within specific therapeutic areas.

The Hyper-C platform has been used to identify new treatment options for focal segmental glomerulosclerosis (FSGS), a rare chronic kidney disease. It has also uncovered potential new indications for the anti-inflammatory drug iguratimod, with a detailed report available online.

Delta 4 partners with clients through two main methods: co-development of drug assets where they handle in-silico discovery while the partner manages preclinical validation, and joining research consortia to apply for grants.

Their services include modeling disease pathobiology, identifying drug targets, enabling drug- and disease-centric repositioning, predicting mechanistic adverse events, and analyzing drug combinations. They also evaluate mechanisms of action within standard-of-care treatments and discover biomarkers.

Clients praise the team's unmatched expertise in AI, their dedication to delivering exceptional results, and the smooth, hassle-free nature of the entire process. Reviewers consistently highlight the high level of professionalism and knowledge displayed by the staff.

Delta 4 is a member of Scientist.com, a platform that streamlines transparency and cooperation between researchers and suppliers. They also received a feature from the Austrian Research Promotion Agency (FFG) for advancing computational biology.

The team consists of highly skilled computational biologists who carefully analyze data to produce unique insights. They leverage a multidisciplinary team with expertise in bioinformatics, molecular biology, IT, pharma, and finance.

Delta 4 helps pharma and biotech companies throughout their entire drug development journey, from early target discovery to clinical trial design. They are particularly suited for those looking to expand indications for existing drugs with known safety profiles.

The website mentions that they apply validated workflows for drug discovery using proprietary disease-drug interference algorithms. They also host one of the largest collections of context-aware molecular models for human diseases.

The company emphasizes that their foundation is based on scientific rationale rather than just data. They aim to provide actionable insights for every stage of a drug development program to help clients find answers faster.

The official website of Delta 4 is delta4.ai.

On Trustburn, Delta 4 has a rating of 4.1 out of 5 based on 11 reviews.